Notably, neoadjuvant regimens combining anti-PD-1 with anti-CTLA-4 or anti-LAG-3 have achieved major pathological response (MPR; defined as ≤ 10% viable tumour cells in the index lymph node) rates of 59% (n = 212, Phase 3 trial) [4] and 63% (n = 30, Phase 2 trial) [6]. The gene discussed is LAG3; the disease is neoplasm.